Achieve Life Sciences, Inc. (FRA:SP4P)
Germany · Delayed Price · Currency is EUR | Market Cap | 720.41M +466.2% |
| Revenue (ttm) | n/a |
| Net Income | -99.82M |
| EPS | -1.58 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 6.90 |
| Previous Close | 6.70 |
| Day's Range | 6.90 - 6.90 |
| 52-Week Range | 2.29 - 7.20 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 7, 2026 |
About Achieve Life Sciences
Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms. It has license and supply agreements with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc., is headquartered in Bothell, Washington. [Read more]
News
Achieve Life Sciences price target lowered to $18 from $20 at Raymond James
Raymond James analyst Ryan Deschner lowered the firm’s price target on Achieve Life Sciences (ACHV) to $18 from $20 and keeps a Strong Buy rating on the shares. The firm…
Achieve Life Sciences initiated with an Overweight at Morgan Stanley
Morgan Stanley analyst Maxwell Skor initiated coverage of Achieve Life Sciences (ACHV) with an Overweight rating and $13 price target Smoking continues to be the leading preventable cause of death,…
Achieve Life Sciences Earnings release: Q2 2026
Achieve Life Sciences released its Q2 2026 earnings on August 11, 2026, summarizing the period's financial results.
Achieve Life Sciences Quarterly report: Q2 2026
Achieve Life Sciences has published its Q2 2026 quarterly earnings report on August 11, 2026.
Achieve Life Sciences reports Q2 EPS (80c), consensus (16c)
“This quarter was about building Achieve to match the significant opportunity of cytisinicline,” said Andrew Goldberg, CEO of Achieve. “We added a commercial team, senior CMC and quality leadership, s...
Achieve Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Updates
Closed a private placement of up to $354 million, with $180 million upfront and up to $174 million from warrants exercisable prior to and up to 20 trading days following FDA approval Strengthened orga...
Achieve Life Sciences initiated with an Outperform at LifeSci Capital
LifeSci Capital initiated coverage of Achieve Life Sciences (ACHV) with an Outperform rating and $17 price target
Achieve Life Sciences Appoints Ronald Dadino and Gloria Cosgrove to Lead CMC, Supply Chain, and Quality
SEATTLE and VANCOUVER, British Columbia, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Achieve or the Company) (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on...
Achieve Life Sciences Announced Granting of New Hire Inducement Awards
SEATTLE and VANCOUVER, British Columbia, July 31, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development a...
Achieve Life Sciences Transcript: AGM 2026
The meeting covered director elections, auditor ratification, executive compensation, and an amendment to increase authorized shares. A quorum was present, voting was completed, and results will be disclosed in a forthcoming Form 8-K.
Achieve Life Sciences added to Russell 2000 Index
Achieve Life Sciences (ACHV) announced that it has been added to the Russell 2000 Index, effective June 26 as part of the Russell U.S. Indexes reconstitution. The company is also…
Achieve Life Sciences Joins Russell 2000® Index
SEATTLE and VANCOUVER, British Columbia, June 29, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Achieve or the Company) (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on...
Achieve Life Sciences resumed with a Strong Buy at Raymond James
Raymond James resumed coverage of Achieve Life Sciences (ACHV) with a Strong Buy rating and $20 price target Achieve’s cytisinicline, supported by Phase 2b and Phase 3 ORCA data, is…
Achieve Life Sciences CRL from FDA cites deficiencies at manufacturing facility
Achieve Life Sciences (ACHV) announced that it has received a complete response letter, or CRL, from the FDA regarding the new drug application, or NDA, for cytisinicline. The CRL relates…
US FDA declines to approve Achieve Life Sciences' smoking-cessation drug
The U.S. Food and Drug Administration has declined to approve Achieve Life Sciences' drug to treat nicotine dependence in adults, the company said on Monday.
Achieve Life Sciences Receives Complete Response Letter from FDA for Cytisinicline NDA
CRL Cites Deficiencies at Third-Party Manufacturing Facility No Efficacy or Clinical Safety Deficiencies Identified SEATTLE and VANCOUVER, British Columbia, June 22, 2026 (GLOBE NEWSWIRE) -- Achieve L...
Achieve Life Sciences Proxy statement: Proxy filing
Achieve Life Sciences filed a proxy statement on June 8, 2026, providing details for shareholder voting and corporate governance matters.
Achieve Life Sciences Appoints Jeffrey Farrow and Reid Waldman, MD to Board of Directors
Appointments Add Deep Biopharmaceutical Commercial Strategy, Clinical and Finance Expertise as Company Advances Toward Potential Cytisinicline Approval and Launch Appointments Add Deep Biopharmaceutic...
Achieve Life Sciences Proxy statement: Proxy filing
Achieve Life Sciences filed a proxy statement on May 29, 2026, providing details for shareholder voting and corporate governance matters.
Achieve Life Sciences Presents Safety Data from 52 Weeks of Continuous Cytisinicline Treatment
ORCA-OL data complete the clinical evidence package supporting the cytisinicline smoking cessation NDA No new safety signals identified by the independent Data Safety Monitoring Committee over 52 week...
Achieve Life Sciences files prospectus for resale of shares by holders
Achieve Life Sciences (ACHV) filed a prospectus relating to the resale by selling shareholders, from time to time, of up to 49.42M shares of common stock.
Achieve Life Sciences Earnings Call Transcript: Q1 2026
Strong capital raise and new leadership position the company for NDA resubmission in Q4 2026 and a first-half 2027 commercial launch, with U.S.-based manufacturing and robust clinical data supporting cytisinicline’s potential as a first-in-class therapy for smoking and vaping cessation.
Achieve Life Sciences Earnings release: Q1 2026
Achieve Life Sciences released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
Achieve Life Sciences Quarterly report: Q1 2026
Achieve Life Sciences has published its Q1 2026 quarterly earnings report on May 12, 2026.
Achieve Life Sciences Registration statement: Registration filing
Achieve Life Sciences filed a registration statement on May 12, 2026, providing details about a securities offering with the SEC.